Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking
Safety Shot, Inc. (Nasdaq: SHOT) has reported groundbreaking clinical results for its rapid alcohol reducer. The double-blind, randomized, placebo-controlled study showed that Safety Shot not only significantly decreases blood alcohol content (BAC) in as little as 30 minutes but also rapidly reduces acetaldehyde in the blood, the main cause of unpleasant after-effects from heavy drinking.
The study demonstrated a substantial increase in aldehyde dehydrogenase and a marked decrease in acetaldehyde, proving that Safety Shot can effectively remove alcohol-related toxins faster than the body's natural processes. This breakthrough addresses the root cause of morning-after symptoms, which is acetaldehydes, not dehydration.
Safety Shot's patented formula is available in a 12oz drink, 4oz shot, and dry powder stick pack, positioning the company as a leader in combating alcohol's negative effects.
Safety Shot, Inc. (Nasdaq: SHOT) ha riportato risultati clinici rivoluzionari per il suo riduttore di alcol rapido. Lo studio in doppio cieco, randomizzato e controllato con placebo ha mostrato che Safety Shot non solo riduce significativamente il contenuto di alcol nel sangue (BAC) in appena 30 minuti, ma anche riduce rapidamente l'acetaldeide nel sangue, principale causa degli effetti indesiderati da consumo eccessivo di alcol.
Lo studio ha dimostrato un incremento sostanziale della deidrogenasi dell'acetaldeide e una marcata diminuzione dell'acetaldeide, dimostrando che Safety Shot può rimuovere efficacemente le tossine legate all'alcol più rapidamente rispetto ai processi naturali del corpo. Questa innovazione affronta la causa principale dei sintomi del giorno dopo, che sono gli acetaldeidi e non la disidratazione.
La formula brevettata di Safety Shot è disponibile in una bevanda da 12oz, un colpo da 4oz e in stick pack di polvere secca, posizionando l'azienda come leader nella lotta contro gli effetti negativi dell'alcol.
Safety Shot, Inc. (Nasdaq: SHOT) ha reportado resultados clínicos innovadores para su reductor de alcohol rápido. El estudio doble ciego, aleatorizado y controlado con placebo mostró que Safety Shot no solo disminuye significativamente el contenido de alcohol en sangre (BAC) en tan solo 30 minutos, sino que también reduce rápidamente el acetaldehído en la sangre, la principal causa de los efectos desagradables del consumo excesivo de alcohol.
El estudio demostró un incremento sustancial en la aldehído deshidrogenasa y una marcada disminución en el acetaldehído, comprobando que Safety Shot puede eliminar eficazmente las toxinas relacionadas con el alcohol más rápido que los procesos naturales del cuerpo. Este avance aborda la causa raíz de los síntomas del día siguiente, que son los acetaldehídos, no la deshidratación.
La fórmula patentada de Safety Shot está disponible en una bebida de 12oz, un disparo de 4oz y en un paquete de polvo seco, posicionando a la empresa como líder en la lucha contra los efectos negativos del alcohol.
Safety Shot, Inc. (Nasdaq: SHOT)는 그들의 빠른 알코올 감소제에 대한 획기적인 임상 결과를 보고했습니다. 단일 맹검, 무작위, 위약 대조 연구에 따르면 Safety Shot은 단 30분 만에 혈중 알코올 농도(BAC)를 유의미하게 감소시킬 뿐만 아니라, 중금주에서 비롯된 불쾌한 후유증의 주 원인인 혈중 아세트알데히드를 신속히 감소시킵니다.
이 연구는 알데히드 탈수소효소의 상당한 증가와 아세트알데히드의 현저한 감소를 입증하여 Safety Shot이 신체의 자연적인 과정보다 알코올 관련 독소를 더 빠르게 제거할 수 있음을 증명했습니다. 이 혁신은 아세트알데히드, 즉 탈수증이 아닌 기분 나쁜 증상의 근본 원인을 다룹니다.
Safety Shot의 특허 받은 포뮬라는 12oz 음료, 4oz 샷 및 드라이 파우더 스틱 팩으로 제공되어, 알코올의 부정적인 영향을 해결하는 데 있어 회사의 선두주자로 자리매김하고 있습니다.
Safety Shot, Inc. (Nasdaq: SHOT) a rapporté des résultats cliniques révolutionnaires pour son réducteur d'alcool rapide. L'étude contrôlée, en double aveugle et randomisée a montré que Safety Shot non seulement réduit considérablement le taux d'alcool dans le sang (BAC) en seulement 30 minutes, mais réduit également rapidement l'acétaldéhyde dans le sang, la principale cause des effets désagréables de l'alcool au lendemain d'une forte consommation.
L'étude a démontré une augmentation substantielle de l'aldéhyde déshydrogénase et une diminution marquée de l'acétaldéhyde, prouvant que Safety Shot peut éliminer efficacement les toxines liées à l'alcool plus rapidement que les processus naturels du corps. Cette avancée s'attaque à la cause première des symptômes du lendemain, qui sont les acétaldéhydes et non la déshydratation.
La formule brevetée de Safety Shot est disponible en boisson de 12oz, en shot de 4oz et en petit paquet de poudre sèche, positionnant l'entreprise comme un leader dans la lutte contre les effets négatifs de l'alcool.
Safety Shot, Inc. (Nasdaq: SHOT) hat bahnbrechende klinische Ergebnisse für seinen schnellen Alkoholreduzierer berichtet. Die doppelblinde, randomisierte und placebokontrollierte Studie zeigte, dass Safety Shot nicht nur den Blutalkoholgehalt (BAC) in nur 30 Minuten erheblich senkt, sondern auch schnell Acetaldehyd im Blut reduziert, der Hauptursache für unangenehme Nachwirkungen beim starken Trinken.
Die Studie zeigte einen deutlichen Anstieg der Aldehyddehydrogenase sowie einen signifikanten Rückgang von Acetaldehyd und beweist, dass Safety Shot Alkohol-assoziierte Toxine schneller aus dem Körper entfernen kann als die natürlichen Prozesse des Körpers. Dieser Durchbruch spricht die wahre Ursache der Kater-Symptome an, die Acetaldehyde und nicht Dehydration sind.
Die patentierte Formel von Safety Shot ist in einer 12oz-Drink, einem 4oz-Shot und als Trockenpulver-Stickpack erhältlich und positioniert das Unternehmen als führend im Kampf gegen die negativen Auswirkungen von Alkohol.
- Clinical study proves Safety Shot significantly reduces BAC and acetaldehyde levels in 30 minutes
- Breakthrough in addressing the root cause of morning-after symptoms from excessive drinking
- Patented formula available in multiple product formats (12oz drink, 4oz shot, dry powder stick pack)
- Potential creation of a new functional beverage category
- None.
Insights
The clinical study results for Safety Shot present a significant breakthrough in addressing alcohol-related discomfort. The double-blind, randomized, placebo-controlled study demonstrates a substantial increase in aldehyde dehydrogenase and a marked decrease in acetaldehyde within 30 minutes of consumption. This is important as acetaldehyde is the primary cause of post-drinking discomfort, not dehydration as commonly believed.
The rapid reduction of both Blood Alcohol Content (BAC) and acetaldehyde levels suggests a novel approach to alcohol metabolism support. This could potentially revolutionize the management of alcohol consumption effects, offering a proactive solution rather than just treating symptoms. However, it's important to note that while promising, further studies may be needed to fully understand long-term effects and potential interactions with other substances.
Safety Shot's clinical results could potentially disrupt the hangover remedy market, estimated at
However, the challenge lies in consumer education and behavior change. The company will need to invest heavily in marketing to shift perceptions from traditional remedies. Additionally, regulatory scrutiny may increase as the product gains popularity, potentially impacting growth. The robust R&D platform mentioned suggests ongoing innovation, which could help maintain a competitive edge in this rapidly evolving market.
The Company Showed a Substantial Reduction in the Physical, Negative Characteristics that Accompany Heavy Drinking in its Recent Groundbreaking, Clinical Study
JUPITER, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”), a wellness company behind the world's first rapid alcohol reducer that lowers blood alcohol content (“BAC”) by supporting its metabolism in as little as 30 minutes -- reported another remarkable finding. In its revolutionary, double-blind, randomized, placebo-controlled study, researchers noted a substantial increase in aldehyde dehydrogenase with a concurrently marked decrease in acetaldehyde (the main culprit of painful feelings after a night of heavy drinking). In as fast as 30 minutes, Safety Shot not only significantly decreased BAC but also rapidly reduced acetaldehyde in the blood by supporting the metabolism of alcohol. This ground-breaking finding proves that it is possible to remove toxins associated with the consumption of alcohol by supporting the metabolism of alcohol in a faster manner than the body can on its own. In addition, Safety Shot reduces these toxins long before any head, body and next day discomfort occurs.
“It is well-established by the medical and scientific communities that acetaldehydes, and NOT dehydration, are the cause of the unpleasant after-affects associated with excessive drinking. Once again, Safety Shot shows not only its superiority to any other product on the market across its broad spectrum of benefits, but that it is clinically proven as the world’s first in attacking the issues before they become a problem,” said David Sandler, the Company’s Chief Operating Officer and Co-Inventor. “Our patented formula and unique process, not only makes you feel better fast, but literally alleviates the painful after-affects commonly seen with excessive alcohol consumption.”
These findings are not only encouraging but are creating an exciting new category of functionality. As part of the Company’s efforts as the world leader in combating the ill effects of alcohol, the team at Safety Shot is committed to furthering its science through its robust R&D platform -- currently offering a 12oz drink, 4oz shot and dry powder stick pack, featuring its patented, clinically proven formula.
About Safety Shot, Inc.
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s Form 10-Q for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on August 15, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
Media and Investor Contact:
Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com
Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com
FAQ
What are the key findings of Safety Shot's clinical study for its alcohol reducer?
How does Safety Shot (SHOT) address morning-after symptoms from excessive drinking?
What product formats are available for Safety Shot's alcohol reducer?
How quickly does Safety Shot (SHOT) work to reduce blood alcohol content?
